Hemostemix Receives Overwhelming Feedback from Doctors and Records First Sales Orders

Strong Start to the Year 2025

Hemostemix (TSXV:HEM; FRA:2VF0) has placed treatments worth $400,000 USD in January 2025 alone since the start of pre-sales for its ACP-01 stem cell therapy. The new patients were generated through a social media campaign and presentations in Puerto Rico. Through the pre-sales of ACP-01, buyers/patients secure early positions on the list for their therapy. By booking early, patients gain the assurance that their treatment is firmly scheduled and when it is expected to take place.

Thomas Smeenk, CEO of Hemostemix commented: “The pre-sales allow Hemostemix to plan for physician time and production time. Our numbers are still modest at present, but the first signed commitments amount to about $400,000 USD, which is a good start for 2025, considering we have 11 months ahead of us.”

The feedback on the Hemostemix therapy that he receives from some treating physicians is overwhelming, Smeenk said: “In my meetings this week with doctors who have treated about 200 patients so far, I am impressed by their response to the same question I ask every doctor I meet who has used ACP-01: ‘Tell me about your patients and what you have observed regarding your patients’ outcomes?’ Yesterday, an invasive cardiologist who has treated 200 patients with ACP in a team of three cardiologists told me: ‘I have used many stem cell products. ACP-01 in the heart is unbeatable; it restores heart function. That is unique. No other autologous stem cells work like ACP-01.'”

Keywords

Disclaimer

I. Information Function and Disclaimer: GOLDINVEST Consulting GmbH offers editors, agencies, and companies the opportunity to publish comments, analyses, and news on www.goldinvest.de. The content serves exclusively for general information and does not replace individual, professional investment advice. It does not constitute financial analyses or sales offers, nor is it a solicitation to buy or sell securities. Decisions made based on the published information are entirely at your own risk. No contractual relationship arises between GOLDINVEST Consulting GmbH and the readers or users, as our information relates exclusively to the company and not to personal investment decisions.

II. Risk Disclosure: The acquisition of securities involves high risks, which can lead to the total loss of the capital invested. Despite careful research, GOLDINVEST Consulting GmbH and its authors assume no liability for financial losses or for the content’s guarantee regarding timeliness, accuracy, appropriateness, and completeness of the published information. Please also note our further terms of use.

III. Conflicts of Interest: In accordance with §34b WpHG and §48f para. 5 BörseG (Austria), we point out that GOLDINVEST Consulting GmbH, as well as its partners, clients, or employees, hold shares in the aforementioned companies. Furthermore, a consulting or other service agreement exists between these companies and GOLDINVEST Consulting GmbH, and it is possible that GOLDINVEST Consulting GmbH may buy or sell shares of these companies at any time. These circumstances can lead to conflicts of interest, as the aforementioned companies compensate GOLDINVEST Consulting GmbH for its reporting.